Tfm Lac: A second isolation of testicular feminization in mice

Tfm ^Lac, a new occurrence of the X-linked mutation testicular feminization, has been isolated in a stock of mice and mapped to the same region as the originalTfm ^H mutation. We compared these two mutants to determine if there are differences in their putative residual androgen receptors or androgen responsiveness. Such differences have been reported forTfm mutations in humans. We found no evidence for induction of ornithine decarboxylase (ODC) activity inTfm ^Lac despite androgen treatment for up to 3 weeks. This is in agreement with findings forTfm ^H. Both of these mutants expressed small amounts of androgen binding activity which shared some properties with the normal androgen receptors in mouse kidney. The binding was distinguishable between the two mutants, however, as determined by hormone saturation experiments utilizing DNA-cellulose chromatography. These findings confirm the independence of the two mutations and are consistent with their being allelic: both result in severe deficits of androgen binding and response.This work was supported by NIH Grants HD17666 and HD20327 (TOF), research grants from the March of Dimes-Birth Defects Foundation (TOF), and a postdoctoral National Research Service Award (J.A.P.) in Endocrinology (AM07337).     

Tonic modulation of anxiety-like behavior by corticotropin-releasing factor (CRF) type 1 receptor (CRF1) within the medial prefrontal cortex (mPFC) in male mice: Role of protein kinase A (PKA)

The medial prefrontal cortex (mPFC) and the neuropeptide corticotropin-releasing factor (CRF) have recently been receiving more attention from those interested in the neurobiology of anxiety. Here, we investigated the CRF pathway in the modulation of anxiety-like behaviors in male mice exposed to the elevated plus-maze (EPM), through intra-mPFC injections of CRF, CP376395 [N-(1-ethylpropyl)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-4-pyridinamine hydrochloride, a CRF type 1 receptor antagonist (CR F1)] or H-89 [N-[2-[[3-(4-bromophenyl)-2-propenyl]amino]ethyl]-5-isoquinolinesulfonamide dihydrochloride, a protein kinase (PKA) inhibitor]. We also investigated the effects of intra-mPFC injections of H-89 on the behavioral effects induced by CRF. Mice received bilateral intra-mPFC injections of CRF (0, 37.5, 75 or 150 pmol), CP376395 (0, 0.75, 1.5 or 3 nmol) or H-89 (0, 1.25, 2.5 or 5 nmol) and were exposed to the EPM, to record conventional and complementary measures of anxiety for 5 min. Results showed that while CRF (75 and 150 pmol) produced an anxiogenic-like effect, CP376395 (all doses) and H-89 (5 nmol) attenuated anxiety-like behavior. When injected before CRF (150 pmol), intra-mPFC H-89 (2.5 nmol, a dose devoid of intrinsic effects on anxiety) completely blocked the anxiogenic-like effects of CRF. These results suggest that (i) CRF plays a tonic anxiogenic-like role at CRF1 receptors within the mPFC, since their blockade per se attenuated anxiety indices and (ii) the anxiogenic-like effects following CRF1 receptor activation depend on cAMP/PKA cascade activation in this limbic forebrain area.